Tonix Pharmaceuticals: Analyst Day Confirms Bullish Thesis, Says Roth Capital
Roth Capital analyst Scott Henry reiterated a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) with a price target of $10.00, which represents a potential upside of 35% from where the stock is currently trading.
Henry said, “TNXP held an analyst update (10/28/2014) with presentations from management and key opinion leaders. We reiterate our Buy rating as we believe that 1) there is a pathway forward for TNX-102 SL to treat fibromyalgia (FM) that has a high probability of success, 2) TNX-102 SL is differentiated through improvement of sleep quality, 3) there are other valuable pipeline compounds, and 4) the current stock valuation of TNXP is compelling, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Scott Henry has a total average return of 10.5% and a 55.2% success rate. Henry has a -11.2% average return when recommending TNXP, and is ranked #411 out of 3354 analysts.